北京健康（控股）有限公司
Beijing Health (Holdings) Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2389)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Reference is made to the annual report of Beijing Health (Holdings) Limited (the "**Company**") for the year ended 31 December 2024 published on 22 April 2025 (the "**2024 Annual Report**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2024 Annual Report. This announcement provides supplemental information to the 2024 Annual Report and should be read in conjunction with the 2024 Annual Report.

SHARE OPTION SCHEME

In addition to the information provided in the 2024 Annual Report, the Company wishes to provide to the shareholders and potential investors of the Company with the following additional information in relation to the 2013 Share Option Scheme pursuant to the Rule 17.07 and 17.09 of the Listing Rules.

(a) Total number of shares available for issue

The total number of shares available for issue under the 2013 Scheme (excluding treasury shares) is 599,889,841 shares representing approximately 9.9% of the issued share capital of the Company as at 31 December 2024. However, since the 2013 Scheme has been expired on 23 May 2023, there is no option could be granted under the 2013 Scheme since then.

(b) Exercise period

An option may be exercised in accordance with the terms of the 2013 Scheme at any time during a period to be determined and notified by the Directors to each grantee, which period may commence on the day on which the offer is made but shall end in any event not later than 10 years from the offer date subject to the provisions for early termination thereof.

(c) Vesting period

Unless the Directors otherwise determined and stated in the offer to the participant, there is no minimum period for which an option granted under the 2013 Scheme must be held before it can be exercised.

(d) The remaining life of the 2013 Scheme

Subject to any early termination determined by the Board in accordance with the terms of the 2013 Scheme, the 2013 Scheme is valid and effective for a term of 10 years commencing on its adoption date (i.e. 24 May 2013). Accordingly, the 2013 Scheme has been expired on 23 May 2023, however, the provisions of the 2013 Scheme shall remain in full force and holders of all options granted under it prior to such termination shall be entitled to exercise the outstanding options pursuant to the terms of it until expiry of the said options.

(e) Movements in the Company's share options outstanding during the year

The following table discloses movements in the Company's share options outstanding during the year:

Name or category of participant	Date of grant of share options	Number of share options: At 1 January 2024	Granted during the year	Exercised during the year	Lapsed during the year	At 31 December 2024	Vesting period of share options	Exercise period of share options	Exercise price of share options *HK$ per share*
Directors, chief executive and a substantial shareholder and their associates									
Mr. Zhu Shi Xing	2 April 2015	20,000,000	–	–	–	20,000,000	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	10,000,000	–	–	–	10,000,000	(ii)	28 January 2016 to 27 January 2017	0.53
		30,000,000	–	–	–	30,000,000			
Mr. Liu Xue Heng	2 April 2015	20,000,000	–	–	–	20,000,000	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	10,000,000	–	–	–	10,000,000	(ii)	28 January 2016 to 27 January 2017	0.53
		30,000,000	–	–	–	30,000,000			
Mr. Gu Shan Chao	2 April 2015	20,000,000	–	–	–	20,000,000	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	10,000,000	–	–	–	10,000,000	(ii)	28 January 2016 to 27 January 2017	0.53
		30,000,000	–	–	–	30,000,000			
Mr. Wang Zheng Chun	2 April 2015	20,000,000	–	–	–	20,000,000	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	10,000,000	–	–	–	10,000,000	(ii)	28 January 2016 to 27 January 2017	0.53
		30,000,000	–	–	–	30,000,000			
Mr. Siu Kin Wai	2 April 2015	10,000,000	–	–	–	10,000,000	(i)	2 April 2016 to 1 April 2025	0.61
Mr. Hu Shiang Chi	2 April 2015	5,000,000			(5,000,000)	–	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	10,000,000			(10,000,000)	–	(ii)	28 January 2016 to 27 January 2017	0.53
		15,000,000	–	–	(15,000,000)	–			

Name or category of participant	Date of grant of share options	Number of share options: At 1 January 2024	Granted during the year	Exercised during the year	Lapsed during the year	At 31 December 2024	Vesting period of share options	Exercise period of share options	Exercise price of share options *HK$ per share*
Mr. Robert Winslow Koepp	2 April 2015	5,000,000			(5,000,000)	–	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	2,000,000			(2,000,000)	–	(ii)	28 January 2016 to 27 January 2017	0.53
		7,000,000	–	–	(7,000,000)	–			
Mr. Wu Yong Xin	2 April 2015	2,000,000	–	–	–	2,000,000	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	2,000,000	–	–	–	2,000,000	(ii)	28 January 2016 to 27 January 2017	0.53
		4,000,000	–	–	–	4,000,000			
Mr. Tse Man Kit, Keith	2 April 2015	2,000,000	–	–	–	2,000,000	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	2,000,000	–	–	–	2,000,000	(ii)	28 January 2016 to 27 January 2017	0.53
		4,000,000	–	–	–	4,000,000			
Mr. Zhang Yun Zhou	28 January 2016	2,000,000	–	–	–	2,000,000	(ii)	28 January 2016 to 27 January 2017	0.53
	Sub-total	162,000,000	–	–	(22,000,000)	140,000,000			
Other employees									
In aggregate	2 April 2015	52,500,000				52,500,000	(i)	2 April 2016 to 1 April 2025	0.61
	28 January 2016	43,500,000				43,500,000	(ii)	28 January 2016 to 27 January 2017	0.53
	Sub-total	96,000,000	–	–	–	96,000,000			
	Total	258,000,000	–	–	(22,000,000)	236,000,000			

Notes:

(i) First 30% of the options granted were vested from 2 April 2016, second 30% of the options granted were vested from 2 April 2017 and remaining 40% of the options granted were vested from 2 April 2018. Upon the lapse of the vesting period, the share options are exercisable until 1 April 2025.

(ii) First 30% of the options granted were vested from 28 January 2017, second 30% of the options granted were vested from 28 January 2018 and remaining 40% of the options granted were vested from 28 January 2019. Upon the lapse of the vesting period, the share options are exercisable until 27 January 2026.

The above additional information does not affect other information contained in the 2024 Annual Report. Save as disclosed above, all other information in the 2024 Annual Report remains unchanged.

By Order of the Board of
Beijing Health (Holdings) Limited
Zhu Shi Xing
Chairman

Hong Kong, 19 May 2025

As at the date of this announcement, the Board comprises five Executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao, Mr. Siu Kin Wai and Mr. Wang Zheng Chun and four Independent Non-Executive Directors, namely Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin, Mr. Zhang Yun Zhou and Ms. Yang Xiao Yan.